Diabetes news

UnitedHealthcare $0 copay

UnitedHealthcare Announces $0 Copay on Insulin, Glucagon + More, Beginning in 2023

UnitedHealthcare announced a $0 copay on insulin, glucagon and other drugs starting in 2023. Here's what that could mean for UHC members.MORE

Research: Practical Use of Closed-Loop Insulin Pumps

Closed-loop insulin pump technology is a game-changer for those taking insulin. Here are essential tips to using them in day-to-day life.MORE

Weight Management + Type 2 Diabetes: Using Compassion, Medicine and Surgery

Weight loss has several benefits for people with type 2 diabetes. However, it isn’t always easy to achieve through only lifestyle changes.MORE

The Future of Insulin — Will It Be Affordable for the People Who Need It?

Research is showing promising advancements with new weekly oral and injectable insulins—but will they actually be affordable?MORE

Diabetes + Dementia: Using Nasal Insulin to Improve Brain Function

With rising rates of obesity in both type 1 and type 2 diabetes, understanding the impact on long-term brain health and function is critical.MORE

Reaching Everyone — Health Disparities in Physical Activity

People living with diabetes are told to just exercise more to better manage their diabetes. Here is why its not that simple. MORE

Race, Racism, and Diabetes Research

Diabetes care and research is still drastically impacted by racist practices. It’s time to call the racism out. MORE

Mounjaro: Its Powerful Potential to Treat Type 2 Diabetes & Obesity

Experts discuss the impressive impact and future potential of using Mounjaro (tirzepatide) to treat obesity and type 2 diabetes.MORE

Diabetes Standards of Care Updated for Preventing or Delaying Type 2 Diabetes

The ADA has updated the standards of care to include recommendations that focus on preventing or delaying type 2 diabetes and its associated complications.MORE

Another Reminder that Racial/Ethnic Inequality Exists in Diabetes Care

Despite the variety of diabetes medications and technology, race and ethnicity still weigh heavily on a person’s access to these life-saving tools.MORE

Access to Insulin: In the United States

Despite the growing variety of insulin and technology, access to this life-saving drug continues to be a dire problem in the United States.MORE

Access to Insulin: In Low-Income Countries

In many countries, a person with diabetes may walk for four days to get a vial of short-acting insulin and seven to 10 days for long-acting.MORE
ATTD 2022

Research Suggests Changing Treatment Approach for Type 2 Diabetes 

With more medication and technology available for treating type 2 diabetes, it's about time more providers make better use of them. MORE

FDA Approves Lilly’s Mounjaro: First of its Kind Medication for Treatment of Type 2 Diabetes

The FDA approved Mounjaro from Lilly, the first GIP/ GLP-1 receptor agonist to treat people with type 2 diabetes. MORE
Tirzepatide research

Promising New Drug Leads to 22.5% Weight Loss in Adults Living with Obesity

The latest study on a new drug is making headlines for its impressive ability to help patients lose weight.MORE

Coverage of Dexcom G6 CGM Now Improved with TRICARE

TRICARE healthcare members can now receive the Dexcom G6 continuous glucose monitor (CGM) under pharmacy benefits.MORE
insulin now act

The Affordable Insulin Now Act: A Step Toward Federal Legislation

The Affordable Insulin Now Act, if passed in its current form, could help bring down the cost of insulin for millions of insured people with diabetes.MORE

FreeStyle Libre 2 Now More Easily Accessible for Military Members Through TRICARE

Military members with TRICARE now have easier access to Abbott’s FreeStyle Libre 2 continuous glucose monitor (CGM).MORE
Breakthrough Device Designation

COVID-19 Pushes FDA Approval of Breakthrough Device Designation for Dexcom CGM in Hospital Settings

The FDA has granted Breakthrough Device Designation for Dexcom CGM in hospital settings after the pandemic highlighted essential care needs for patients with diabetes.MORE
Eversense E3

Eversense E3 Continuous Glucose Monitor Gains FDA Approval, Offers Extended Wear-Time

The Eversense E3 continuous glucose monitor (CGM) is an exciting advancement for the diabetes community, with improved wear-time and accuracy.MORE
Drug Pricing Investigation

Inside the Drug Pricing Investigation from the House Oversight and Reform Committee

The results of the most recent report from the committee make things clear for the United States — the need for access to affordable healthcare is direr than ever.MORE
Build Back Better

The Potential Impact of Build Back Better on American Healthcare

Dive into the basics of Build Back Better, why people with diabetes should follow the bill as it progresses, and the impact it could have on your health.MORE
Mark Cuban Pharmacy

Mark Cuban’s New Online Pharmacy Provides Affordable Access to Some Common Prescription Drugs

Mark Cuban's latest investment in the pharmaceutical industry offers common generic prescription medications (not including insulin) at a fraction of the cost.MORE

Lilly Issues Voluntary Nationwide Recall of One Lot of Glucagon Emergency Kit

Lilly Diabetes announced the voluntary recall of lot D239382D, Expiration April 2022 of Glucagon Emergency Kits.MORE
Latinx Diabetes Initiative

The Latinx Diabetes Initiative Provides Culturally Tailored Care To Latinx Patients With Diabetes

Andreina Millan Ferro is centering culturally sensitive diabetes care for Latinx patients with diabetes at the Latinx Diabetes Initiative.MORE
Yarishdy Mora

Yarishdy Mora Is Empowering Youth Through Diabetes Education In Mexico

Yarishdy Mora is the director of the Youth Health Program for Project HOPE in Mexico. She creates platforms that help youth learn about diabetes. MORE
pandemic homelessness

Pandemic Homelessness Disproportionately Impacts People With Diabetes

An American Diabetes Association report found that pandemic homelessness hit people with diabetes 48 times harder.MORE

Youth with T2D Experience Long-Term Complications By Young Adulthood

Type 2 diabetes cases are rising in children and we're starting to learn they experience long-term complications by young adulthood. MORE

Abbott’s FreeStyle Libre 2 App Receives FDA Clearance

On August 2, 2021, the FDA approved the FreeStyle Libre 2 app for adults and children with diabetes, allowing user to access glucose readings directly from their iPhone.MORE

FDA Approves Senza®, Nevro’s High Frequency Spinal Cord Stimulation Therapy For PDN

The Senza System has been approved by the FDA for the treatment of chronic pain associated with painful diabetic neuropathy. MORE

Semglee Receives FDA Approval as First Interchangeable Biosimilar Insulin

Semglee becomes the first interchangeable biosimilar product for the treatment of Type 1 and Type 2 diabetes.MORE
Culturally Sensitive LGBTQ+ Diabetes Health Care

Providing Culturally Sensitive LGBTQ+ Diabetes Health Care

Culturally sensitive LGBTQ+ diabetes health care can decrease stigma and advance diabetes care access for the LGBTQ community. MORE

FDA Approves Kerendia For The Treatment Of Type 2 Diabetes

Kerendia will be available in the U.S. immediately for the treatment of chronic kidney disease associated with Type 2 diabetes.MORE
Walmart NovoLog

Walmart Launches Lower-Cost Analog Insulin: ReliOn NovoLog

ReliOn NovoLog will be available at Walmart and Sam's Club pharmacies for $72.88 per vial and $85.88 per box of five FlexPens.MORE

News from DiabetesMine™ D-Data Exchange 2021

D-Data is the event, where attendees can discover, learn about, and try demos of new diabetes tech. Here is a recap of the sessions we attended at D-Data 2021.MORE

Zegalogue® Is Now Commercially Available In The United States

Zegalogue®, also known as dasiglucagon, is now commercially available in the U.S. for the treatment of severe hypoglycemia.MORE

American Diabetes Association’s 81st Annual Scientific Sessions: #ADA2021

The biggest diabetes conference of the year is virtual for the second year + Beyond Type 2 is reporting live! Keep up with our coverage here. MORE
continuous glucose monitor coverage

Medicare Loosens Restrictions On Continuous Glucose Monitor Coverage

Medicare revised its local coverage determination policy to remove requirements for continuous glucose monitor coverage.MORE
ACA intact

Supreme Court Votes To Keep The ACA Intact

The Affordable Care Act (ACA) provides health care to millions of Americans. The Supreme Court voted 7-2 to keep the ACA intact.MORE
vaccine access

COVID-19 Vaccines And Diabetes: Vaccine Access Issues For People Of Color

Communities of color with diabetes face a myriad of barriers when it comes to vaccine access. Experts share how the U.S. can achieve vaccine equity.MORE
omnipod 5

Omnipod 5 Pivotal Trial Data Published

Data from the pivotal trial shows that the Omnipod 5 improves time-in-range, and reduces HbA1c and mean glucose levels. MORE
lessons about diabetes

ATTD 2021: Lessons About Diabetes During The COVID-19 Pandemic

ATTD 2021 took place from June 2-5. Dr. Irl Hirsch shares his lessons about diabetes during the COVID-19 pandemic.MORE
ATTD 2021

Breaking News From ATTD 2021

This year, ATTD 2021 will be held virtually where developers and clinicians will present their new diabetes technology and research.MORE
mental health concerns

The Pandemic Increased Mental Health Concerns Among People With Diabetes

Cecelia Health conducted a survey that revealed increased mental health concerns among people with diabetes during the COVID-19 pandemic. MORE
sharp drop in a1c testing due to telehealth

COVID Pandemic Leads to a Sharp Drop in A1c Testing

"We started getting a lot of referrals with really high A1cs in the double-digits,” says Jennifer Okemah, MS, RD, BCADM, CDCES, CSSDMORE

Researchers Find That CGMs Provide Insight On The Progression Of Type 2 Diabetes Among Hispanic Adults

Researchers break down the importance of CGMs in understanding diabetes and how to tackle accessibility barriers among Hispanic adults. MORE

Combating Bullying: How One Person With Diabetes Fought To Test Her Blood Sugar In The Workplace

Sheri Byrne shares her experience on how she fought workplace bullying due to diabetes and advocated for herself.MORE
Bigfoot Unity

Bigfoot Unity™ Diabetes Management System Receives The Green Light From The FDA

Bigfoot Unity™, a one-of-a-kind diabetes management system with smart pen caps received FDA approval on May 10, 2021 and will reach select diabetes clinics this spring. MORE

Asian Isn’t A Monolith: Why More Specific Data Matters in Diabetes Research

Data on how diabetes impacts specific ethnic groups could help us better support people within Asian American Pacific Islander communities.MORE

Diabetes + Ramadan: Here’s How a Few People Are Observing

People with diabetes face their own set of challenges when observing Ramadan. Two people with diabetes share their experiences. MORE
aapi diabetes research

Chris Hahm’s Uphill Battle: The Severe Underfunding of AAPI Diabetes Research

H. Chris Hahm shares her challenges of conducting diabetes research focused on the AAPI community, research that is severely underfunded.MORE

Doctors Agree: They Need More Time with Type 2 Diabetes Patients

90% of doctors want more time with Type 2 diabetes patients and better communication between specialists regarding each patient.MORE

Two Pillars in the Diabetes Community Unite to Serve Millions Living with Diabetes

The partnership will feature combined resources, strategies, and tactics to better serve people living with type 1 diabetes, type 2 diabetes, and prediabetes.MORE

The AHA and ADA Award Community Grants to Help Improve Cardiovascular Risks in Type 2 Diabetes Patients

The American Heart Association and American Diabetes Association awarded up to $900,000 in community grants to help lower the risks of cardiovascular events in people with Type 2 diabetes.MORE

Get the Facts on Insulin Pricing + The Presidential Transition

A flurry of misinformation is stoking fears that the Biden Admin paused or reversed a previous Trump Admin policy that lowered the price of insulin. MORE

New Year, New Administration: What’s Coming For US Healthcare Policy

With a new governmental administration, it is likely we will see notable and impactful movement in healthcare policy. What can we expect? MORE

Beyond Type 2 Celebrates Two Years, Launches New Community Platform

Today, global diabetes nonprofit Beyond Type 1 celebrates the two year anniversary of the launch of Beyond Type 2 - a digital platform for those impacted by Type 2 diabetes, available in English and S...MORE

Study Finds Lilly’s Tirzepatide Reduces A1C and Body Weight

After a 52-week treatment plan, a study conducted by Eli Lilly and Company found that their new medication tirzepatide significantly reduced A1C and body weight in adults with Type 2 diabetes.MORE

Diabetes + COVID Vaccines: What You Need to Know

If you have diabetes, here’s what you need to know about the COVID-19 vaccines, including safety, timeline, and how to get yours.MORE

An Interview with ADCES 2020 Innovative Use of Technology Award Winner, Molly Wagman

2020 Innovative Use of Technology Award winner, Molly Wagman, MS, RDN, CSSD, CDCES, talks to Beyond Type 2 about using mySugr to improve the lives of diabetes patients. MORE

Study Shows Meal Replacement Shakes Improve T2D Glucose Management

New study reveals twice-daily meal replacement shakes improve glucose management in people with type 2 diabetes who are on oral medication. MORE

White House Issues Executive Orders Taking Aim at Drug Prices

On Friday, July 24 President Trump announced and signed four Executive Orders aimed at lowering prescription drug prices in the U.S.MORE

Who Has Access to New Oral Diabetes Medications?

Racial and ethnic minorities may have a greater need for newer diabetes medications but functionally have less access. MORE

FreeStyle Libre 2 Approved for Use in U.S.

The FreeStyle Libre 2 is a 14 day CGM system that transmits data every minute and now includes customizable high and low alerts without the need to scan the device. The Abbott announcement says it wil...MORE

How Omnipod Simplifies Life with Type 2 Diabetes: A Chat with Insulet CCO Bret Christensen

Bret Christensen is the Chief Commercial Officer at Insulet, maker of the Omnipod Insulin Management System. He recently spoke with Beyond Type 2 to discuss his role at the company, how Insulet is ove...MORE

American Diabetes Association’s 80th Annual Scientific Sessions: #ADA2020

The biggest diabetes conference of the year is taking place virtually and Beyond Type 2 is reporting live! Learn more, stay tuned.MORE

Medicare Part D Senior Savings Model Caps Insulin Costs at $35 per Month

The Senior Savings Model caps out of pocket insulin costs at $35 per month for seniors enrolled in eligible plans.MORE

England’s NHS Releases Study on Risk of COVID-19 for People with Diabetes

This week, the National Health Service (NHS) in England released the first study of its kind, breaking down COVID-19 mortality risk by type of diabetes.MORE

Roche Offers Free Access to mySugr Pro During COVID-19

With the rise of telemedicine during COVID-19, free access to mySugr Pro will help people stay connected to their healthcare team. MORE

The JDRF – Beyond Type 1 Alliance Releases Recommendations for People with Diabetes During COVID-19 Pandemic

The recommendations are supported by 50 international organizations working together to curb the spread of COVID-19 and protect those most vulnerable.MORE

Novo Offers Free 90-Day Insulin Supply to People Recently Uninsured Due to COVID-19

Novo Nordisk announces program offering a free 90-day supply of Novo Nordisk insulin for those who have recently lost their health insurance coverage due to a change in job status because of COVID-19....MORE

FreeStyle Libre Approved by FDA for Hospitalized Patients During COVID-19 Pandemic

Abbott's FreeStyle Libre 14 day system will allow doctors to remotely monitor their patient's glucose levels. MORE

New Program Offers $35 Monthly Copays for Lilly Insulins

Eli Lilly announced a new program that allows people in the US to fill their monthly prescription of Lilly insulin for $35 per month with a copay card.MORE

Senseonics Suspends Commercial US Sales of Eversense in Response to COVID-19

On March 26, Senseonics suspended all commercial sales of the Eversense continuous glucose monitor (CGM) in the United States.MORE

The Power in Numbers: Change.org’s Affordable Insulin For All Movement

As insulin prices continue to increase in the United States, Change.org is equipping those affected with the tools to speak out.MORE

Beyond Type 1 Welcomes New Members to Leadership Council 

The new additions bring a richness of expertise and perspective, representing the Type 1 and Type 2 diabetes communities.MORE

The Diabetes Disaster Response Coalition Coronavirus Response

On March 12, the Diabetes Disaster Response Coalition (DDRC) circulated an update to coalition members in response to coronavirus (COVID-19). Here are the steps the organization is taking and other im...MORE

New Medicare Plan Will Cap Insulin Copays at $35

Today, the Centers for Medicare & Medicaid Services (CMS) launched a new plan for some Medicare Part D participants to pay a maximum $35 copay for their monthly supply of insulin. MORE

Omnipod Closed Loop Technology to be Compatible with Both Abbott and Dexcom CGMs

Abbott and Dexcom announced formal partnerships with Insulet to be compatible as CGMs on the Omnipod Horizon Automated Insulin Delivery System. MORE

FDA Approves Triple Combination Pill Trijardy for Type 2 Diabetes

On January 27, 2020, the U.S. Food and Drug Administration (FDA) approved Trijardy XR, a triple combination drug of empagliflozin (Jardiance), linagliptin (Tradjenta), and metformin. This is the first...MORE

AADE Rebrands, Changes Name to ADCES

On January 22, 2020, the organization formerly known as the American Association of Diabetes Educators (AADE) announced a change to the organization's name to the Association of Diabetes Care and...MORE

Beyond Type 2 Celebrates One Year Anniversary, Adds New Partner

Today, global diabetes non-profit Beyond Type 1 celebrates the one year anniversary of the launch of Beyond Type 2 - a platform and community serving those impacted by Type 2 diabetes. In 2020, Beyond...MORE

Researchers See Type 2 Diabetes Develop for the First Time

Researchers have seen Type 2 diabetes (T2D) develop for the first time. A study published this month in Cell Metabolism shows excess fat that spills over from the liver into the pancreas may cause T2D...MORE

FDA Investigating Contaminated Metformin, Risk is Low for Type 2 Patients

The FDA, Health Canada, and European Union investigate the presence of cancer-causing NDMA in Type 2 diabetes drug, metformin. The risk to patients is very low.MORE

Abbott and Omada Health Partner to Help People With Type 2 Diabetes

On October 14, 2019, Abbott and Omada Health announced a partnership to integrate Abbott's FreeStyle Libre continuous glucose monitoring system (CGM) with Omada Health's digital program for ...MORE

Farxiga Approved in the United States to Treat Heart Failure

On Monday, October 21, 2019, the U.S. Food and Drug Administration (FDA) approved AstraZeneca's diabetes drug, Farxiga, for use in the U.S. to treat and reduce the risks of hospitalization from h...MORE

Abbott’s FreeStyle Libre Receives Reimbursement in Ontario and Quebec

Abbott FreeStyle Libre announced on Friday, September 13, 2019, it received public reimbursement in Canada's two largest provinces, Ontario and Quebec, for it's FreeStyle Libre System. The n...MORE

FDA Approves Invokana to Treat Diabetic Kidney Disease

On Monday, September 30, 2019, the U.S. Food and Drug Administration (FDA) approved a new indication for the Janssen Pharmaceutical Companies of Johnson & Johnson's INVOKANA (canagliflozin) t...MORE

FDA Approves First Oral Semaglutide Rybelsus from Novo Nordisk

On September 20, the FDA approved the first oral GLP-1 Rybelsus (semaglutide). Manufactured by Novo Nordisk, the GLP-1 drug showed impressive efficacy in the PIONEER Trial results presented at EASD 20...MORE

Study Shows Combination Therapy Leads to Better Outcomes for Newly Diagnosed T2D Patients

The new study shows combination therapy in patients newly diagnosed with type 2 diabetes provides better outcomes than metformin alone.MORE

FDA Approves First Ready-to-Use Liquid Stable Glucagon Gvoke

On September 10 the FDA approved the Gvoke HypoPen and Gvoke PFS, emergency glucagon rescue devices for the treatment of severe hypoglycemia.MORE

Half-Price Generics of NovoLog and NovoLog Mix Announced by Novo Nordisk

Novo Nordisk announced that authorized generic versions of NovoLog and NovoLog Mix will be made available on January 2, 2020.MORE

People With Diabetes Forgoing Basic Needs in Order to Survive According to New Studies

According to two studies presented at the American Association of Diabetes Educators 2019 Annual Conference, people with diabetes are forgoing basic needs in the face of rising healthcare costs and ta...MORE

Nasal Glucagon Baqsimi Approved by the FDA

On Thursday, the Food and Drug Administration approved Eli Lilly and Company's Baqsimi, a non-injectable, nasal glucagon and the first of its kind. MORE

Non-Insulin Drug Approved for Kids with Type 2 Diabetes by FDA

Victoza, a liraglutide injection, was approved by the U.S. Food and Drug Administration. It's the first non-insulin drug approved for pediatric use in nearly 20 years.MORE

Colorado Becomes First State to Pass Bill Capping Insulin Costs

On Wednesday, May 22, Colorado became the first state in the U.S. to put a price cap on insulin.MORE

Express Scripts Won’t Cover Lilly’s Generic Insulin

The largest PBM in the U.S. recently released a list of formulary exclusions that included 'Insulin Lispro' as an excluded medication. MORE

Previously Healthy from Beyond Type 1 Named Webby People’s Voice Award Winner

Hailed as the “Internet’s highest honor” and “the Oscars of the Internet” The Webby Awards are presented by the International Academy of Digital Arts and Sciences (IADAS) honoring excellence...MORE

Insulin Manufacturers and PBMs Testify Before Congress

The hearing was contentious throughout, with House members grilling both the manufacturers and the PBM representatives about the reasons for high costs.MORE


On Monday, March 4, Lilly Diabetes announced in a press release that an authorized generic version of Humalog insulin will be available in United States pharmacies for half the list price of Humalog...MORE